Abstract:Abstract Accurate monitoring of orthotopic tumors in oncological research is critical. While conventional surgical exposure method or imaging methods such as bioluminescence imaging (BLI), ultrasound imaging (US) and computed tomography (CT) have different advantages and limitations. Magnetic Resonance Imaging (MRI) offers a non-invasive modality with high sensitivity. This study compares BLI and MRI in tracking tumor progression, focusing on the human glioblastoma multiforme (GBM) orthotopic xenograft mouse model. To establish the GBM model, human glioblastoma cells U87 MG-luc, expressing firefly luciferase, were intracranially implanted in female BALB/c nude mice. In-life tumor growth was assessed longitudinally every 3-4 days using BLI (IVIS Lumina S5, PerkinElmer, US) and MRI (Bruker BioSpec 117/16, 11.7T ultra-high field scanner, Germany) with a T2-weighted sequence. Mice were randomized into two groups (n=8) based on the MRI-derived tumor volume and BLI signal on the 3rd day post inoculation. One day after grouping, each cohort received specific treatments: one with the standard vehicle control and the other with Temozolomide (TMZ) (10mg/kg, 5 days/week, oral gavage). This treatment lasted until day 21, after which whole brains were removed and tumors excised from surrounding normal tissue and weighed. The results from both BLI and MRI showed that the control group exhibited consistent tumor growth, while TMZ treatment significantly inhibited tumor growth by day 21. However, some differences were observed, particularly for small tumor size, with more accurate measurement with MRI compared to BLI. By day 7 (3 days post treatment), MRI indicated a Tumor Growth Inhibition (TGI) of 32.63%, whereas BLI indicated a 5.04% increase in the TMZ-treated group compared to the control group. From day 11 onwards, both methods demonstrated a TGI exceeding 70% with TMZ treatment. Moreover, there was a pronounced difference in tumor weight correlations: MRI assessments showed a strong correlation (R2=0.9967) with extracted tumor weights, whereas in contrast to BLI showed a weaker correlation (R2=0.5371). The lower correlation for BLI, could be explained by the hypoxia and necrosis commonly observed in larger tumors or after treatment leading to decrease of ATP and reduction of bioluminescence. BLI offers rapid 2D imaging but lacks precision in determining location and depth of GBM tumor. Moreover, it requires luciferase engineered cell lines. In contrast, MRI provides high-resolution 3D imaging without genetic modifications, providing precise anatomical evaluations. Our study highlights the advantages of MRI over BLI for longitudinal monitoring of orthotopic GBM models. MRI imaging modality opens the possibility to use more clinically relevant patient derived xenograft (PDX) models of GBM in an orthotopic manner, improving the clinical transability to evaluate new GBM treatment modalities. Citation Format: Mingrui Guo, Ruisong Su, Jeff W H Chor, Zheyan Zhang, Mandy Tan, Xing Qi Teo, Haosheng Feng, Kuan J. Lee, Li Hua, Longyun Zhang, Jie Cai, Guanping Mao, Jingjing Wang, Keefe Chng, Weiping Han, Colin Guo. Magnetic resonance imaging and bioluminescence imaging for evaluating tumor burden in orthotopic glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4179.

Non-invasive Monitoring of the Kinetic Infiltration and Therapeutic Efficacy of Nanoparticle-Labeled Chimeric Antigen Receptor T Cells in Glioblastoma Via 7.0-Tesla Magnetic Resonance Imaging

Multimodal In Vivo Tracking of Chimeric Antigen Receptor T Cells in Preclinical Glioblastoma Models

In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma

Noninvasive longitudinal PET/CT imaging of CAR T cells using PSMA reporter gene

Direct and Indirect Chimeric Antigen Receptor T-Cell Imaging with PET/MRI in a Tumor Xenograft Model

In vivo imaging of nanoparticle-labeled CAR T cells

MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma

Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring

In Vivo Magnetic Resonance Imaging of CD8+ T Lymphocytes Recruiting to Glioblastoma in Mice

Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles.

Feasibility Study of 68 Ga-labeled CAR T Cells for in Vivo Tracking Using Micro-Positron Emission Tomography Imaging

Magnetic resonance and photoacoustic imaging of brain tumor mediated by mesenchymal stem cell labeled with multifunctional nanoparticle introduced via carotid artery injection

Retargeted Human Avidin-Car T Cells for Adoptive Immunotherapy of Egfrviii Expressing Gliomas and Their Evaluation Via Optical Imaging

NIMG-01. MRI VIRTUAL BIOPSY AND TREATMENT OF PRIMARY OR BRAIN METASTATIC TUMORS WITH TARGETED NANOBIOCONJUGATES

Abstract 4179: Magnetic resonance imaging and bioluminescence imaging for evaluating tumor burden in orthotopic glioblastoma

A transferrin receptor targeting dual-modal MR/NIR fluorescent imaging probe for glioblastoma diagnosis

In Vivo MR Imaging of Glioma Recruitment of Adoptive T-Cells Labeled with NaGdF4 -TAT Nanoprobes.

Image-guided chemotherapy with specifically tuned blood brain barrier permeability in glioma margins

Monitoring Tumor Targeting and Treatment Effects of IRDye 800CW and GX1-Conjugated Polylactic Acid Nanoparticles Encapsulating Endostar on Glioma by Optical Molecular Imaging.

In Vivo Tracking of Superparamagnetic Iron Oxide Nanoparticle-Labeled Mesenchymal Stem Cell Tropism to Malignant Gliomas Using Magnetic Resonance Imaging. Laboratory Investigation.

Feasibility study of 68Ga-labeled CAR T cells for in vivo tracking using micro-positron emission tomography imaging